Gadoversetamide

Summary of Use during Lactation

Gadoversetamide has been withdrawn from the market in the US and several other countries. There is no published experience with gadoversetamide during breastfeeding. Gadoversetamide releases more free gadolinium than some other gadolinium-containing contrast agents. Some European guidelines recommend a 24-hour interruption of breastfeeding after a dose, but guidelines developed by North American professional organizations state that breastfeeding need not be disrupted after a nursing mother receives a gadolinium-containing contrast medium.[1-4]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Gadobutrol, Gadoteridol, Gadoterate

References

1.

Copel J, El-Sayed Y, Heine RP, et al. Committee Opinion No. 723: Guidelines for diagnostic imaging during pregnancy and lactation. Obstet Gynecol 2017;130:e210-e6. [PubMed: 28937575]

2.

American College of Radiology Committee on Drugs and Contrast Media. Administration of contrast media to breast-feeding mothers. In, ACR manual on contrast media. 2023;Version 2023:120-1. https://www​.acr.org/Clinical-Resources​/Contrast-Manual

3.

European Society of Urogenital Radiology. ESUR guidelines on contrast media. 2018;Version 10.0. http://www​.esur-cm.org/index.php/en/

4.

Bookwalter CA, McDonald RJ, Packard AT, et al. Contrast media in pregnant and lactating patients, from the AJR special series on contrast media. AJR Am J Roentgenol 2024. [PubMed: 39046138]

Substance Name

Gadoversetamide

CAS Registry Number

131069-91-5

Drug Class

Breast Feeding

Lactation

Milk, Human

Contrast Media

Diagnostic Agents